Combined sorafenib and yttrium-90 radioembolization for the treatment of advanced hepatocellular carcinoma.

ABSTRACT:

Background and aims

In this pilot study, we assessed the safety and tolerability of combining sorafenib with ⁹⁰Y radioembolization for the treatment of unresectable hepatocellular carcinoma (hcc).

Methods

The study, conducted prospectively during 2009-2012, included eligible patients with unresectable hcc and a life expectancy of at least 12 weeks. Each patient received sorafenib (400 mg twice daily) for 6-8 weeks before ⁹⁰Y treatment. Safety and tolerability were assessed.

Results

Of the 40 patients enrolled, 29 completed treatment (combined therapy). In the initial cohort, the most common cause of hcc was hepatitis C (32.5%), and most patients were staged Child A (82.5%). The 29 patients who completed the study had similar baseline characterist

SUBMITTER: Salman A 

PROVIDER: S-EPMC5081020 | biostudies-literature | 2016 Oct

REPOSITORIES: biostudies-literature